CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.016
https://www.valueinhealthjournal.com/article/S1098-3015(18)33316-3/fulltext
Title :
CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33316-3&doi=10.1016/j.jval.2018.09.016
First page :
Section Title :
Open access? :
No
Section Order :
1152